Multiple Myeloma
April 2017 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Sincerely,
Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Multiple Myeloma: Diagnosis and Treatment.
Authors:Michels TC, Petersen KE
Institution:Madigan Army Medical Center Family Medicine Residency, Tacoma, WA, USA.
Journal:Am Fam Physician. 2017 Mar 15;95(6):373-383.

2:Risk of vertebral compression fractures in multiple myeloma patients: A finite-element study.
Authors:Anitha D, Thomas B, Jan KS, Subburaj K
Institution:aEngineering Product Development (EPD), Singapore University of Technology and Design (SUTD), Singapore bDepartment of Radiology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany.
Journal:Medicine (Baltimore). 2017 Jan;96(2):e5825. doi: 10.1097/MD.0000000000005825.

3:Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
Authors:Jimenez-Zepeda VH, Duggan P, Neri P, Tay J, Bahlis NJ
Institution:Department of Medical Oncology and Hematology, Tom Baker Cancer Center, 1331 29th St, NW, Calgary, AB, T2N 4N2, Canada. Victor.Zepeda@albertahealthservices.ca. St, NW, Calgary, AB, T2N 4N2, Canada. St, NW, Calgary, AB, T2N 4N2, Canada. St, NW, Calgary, AB, T2N 4N2, Canada. St, NW, Calgary, AB, T2N 4N2, Canada.
Journal:Ann Hematol. 2017 Mar;96(3):431-439. doi: 10.1007/s00277-016-2901-x. Epub 2017 Jan 10.

4:Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Authors:Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L, Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R
Institution:Department of Hematology, Tel-Aviv Sourasky Medical Center, Institute of Hematology, Weizman St. 6, Tel Aviv, Israel. yaelcoh@tlvmc.gov.il. yaelcoh@tlvmc.gov.il. Campus, Haifa, Israel. Tikva, Israel. Tikva, Israel. Campus, Haifa, Israel. Tikva, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel. Campus, Haifa, Israel. Hematology, Weizman St. 6, Tel Aviv, Israel.
Journal:Ann Hematol. 2017 Feb;96(2):271-278. doi: 10.1007/s00277-016-2882-9. Epub 2016 Dec 30.

5:Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Authors:Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL
Institution:Helen F. Graham Cancer Center & Research Institute, Newark, Delaware. Connecticut. Regeneron Pharmaceuticals, Basking Ridge, New Jersey. Minnesota. American Society of Clinical Oncology, Alexandria, Virginia.
Journal:JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.

6:Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Authors:Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR
Institution:Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. USA. West Hollywood, CA, 90069, USA. USA. USA. USA. West Hollywood, CA, 90069, USA. jberenson@imbcr.org. USA. jberenson@imbcr.org. jberenson@imbcr.org.
Journal:Ann Hematol. 2017 Mar;96(3):449-459. doi: 10.1007/s00277-016-2889-2. Epub 2016 Dec 8.

7:Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Authors:Berenson A, Vardanyan S, David M, Wang J, Harutyunyan NM, Gottlieb J, Halleluyan R, Spektor TM, Udd KA, Eshaghian S, Nassir Y, Eades B, Swift R, Berenson JR
Institution:Institute for Myeloma & Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. West Hollywood, CA, 90069, USA. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. West Hollywood, CA, 90069, USA. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. West Hollywood, CA, 90069, USA. jberenson@imbcr.org. W. Sunset Blvd, Suite 310, West Hollywood, CA, USA. jberenson@imbcr.org. jberenson@imbcr.org.
Journal:Ann Hematol. 2017 Mar;96(3):441-448. doi: 10.1007/s00277-016-2888-3. Epub 2016 Dec 2.

8:Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Authors:Offidani M, Corvatta L, Bringhen S, Gentili S, Troia R, Maracci L, Larocca A, Gay F, Leoni P, Boccadoro M
Institution:Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy. Ancona, Ancona, Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Ancona, Ancona, Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Ancona, Ancona, Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy. Ancona, Ancona, Italy. Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Italy.
Journal:Eur J Haematol. 2017 Mar;98(3):289-295. doi: 10.1111/ejh.12834. Epub 2017 Jan 5.

9:Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.
Authors:Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH
Institution:Department of Stem Cell Transplantation and Cellular therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA. TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA. MD Anderson Cancer Center, Houston, TX, USA.
Journal:Eur J Haematol. 2017 Mar;98(3):263-268. doi: 10.1111/ejh.12826. Epub 2016 Dec 1.

10:Association between complete response and outcomes in transplant-eligible myeloma patients in the era of novel agents.
Authors:van de Velde H, Londhe A, Ataman O, Johns HL, Hill S, Landers E, Berlin JA
Institution:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Journal:Eur J Haematol. 2017 Mar;98(3):269-279. doi: 10.1111/ejh.12829. Epub 2016 Dec 17.

11:Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
Authors:Schabel C, Horger M, Kum S, Weisel K, Fritz J, Ioanoviciu SD, Bier G
Institution:Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Eberhard-Karls-University Tuebingen, Otfried-Muller-Str. 5, 72076 Tuebingen, Germany. Hopkins University School of Medicine, 600 N Wolfe St., Baltimore, MD 21287, USA. Dima Str. 5, 300079 Timisoara, Romania. Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany. Electronic address: georg.bier@med.uni-tuebingen.de.
Journal:Eur J Radiol. 2016 Dec;85(12):2195-2199. doi: 10.1016/j.ejrad.2016.10.015. Epub 2016 Oct 17.

12:Spine stereotactic radiosurgery for the treatment of multiple myeloma.
Authors:Miller JA, Balagamwala EH, Chao ST, Emch T, Suh JH, Djemil T, Angelov L
Institution:Cleveland Clinic Lerner College of Medicine.
Journal:J Neurosurg Spine. 2017 Mar;26(3):282-290. doi: 10.3171/2016.8.SPINE16412. Epub 2016 Oct 28.

13:Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Authors:Mateos MV, Oriol A, Martinez-Lopez J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS
Institution:Servicio de Hematologia, Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Paseo San Vicente 58-182, Salamanca, 37007, Spain. mvmateos@usal.es. Institut Catala d'Oncologia (ICO), Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucemia Josep Carreras (IJC), Barcelona, Spain. Tempranos, Madrid, Spain. Spain. Donostia - San Sebastian (Guipuzcoa), Spain. Instituto de Investigacion Sanitaria (ISS) de Aragon, Zaragoza, Spain. Meseguer, Murcia, Spain. Spain.
Journal:Ann Hematol. 2016 Dec;95(12):2033-2041. Epub 2016 Oct 14.

14:Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
Authors:Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM
Institution:Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Journal:JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.

15:Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Authors:Majer I, van de Wetering G, Polanyi Z, Krishna A, Gray E, Roy A
Institution:Pharmerit International, Health Economics and Outcomes Research, Marten Meesweg 107, 3068 AV, Rotterdam, The Netherlands. 107, 3068 AV, Rotterdam, The Netherlands. gvandewetering@pharmerit.com.
Journal:Appl Health Econ Health Policy. 2017 Feb;15(1):45-55. doi: 10.1007/s40258-016-0271-0.

16:Improved survival of older patients with multiple myeloma in the era of novel agents.
Authors:Mey UJ, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F
Institution:Medical Oncology and Hematology, Kantonsspital Graubunden, Chur, Switzerland. Innsbruck, Austria.
Journal:Hematol Oncol. 2016 Dec;34(4):217-223. doi: 10.1002/hon.2205. Epub 2015 Apr 21.

17:Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
Authors:Breitkreutz I, Becker N, Benner A, Kosely F, Heining C, Hillengass J, Egerer G, Ho AD, Goldschmidt H, Raab MS
Institution:Max-Eder-Group 'Experimental Therapies for Hematologic Malignancies', Department of Medicine V, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany. Germany. Heidelberg, Germany. Germany. of Medicine V, Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Journal:Hematol Oncol. 2016 Dec;34(4):200-207. doi: 10.1002/hon.2199. Epub 2015 Mar 18.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount


Medifocus Guidebook on Multiple Myeloma

Updated: January 29, 2017
189 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MM72409995

Coupon Expires: May 28, 2017



What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
K.J.
Milwaukee, Wisconsin


"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
J.M.
New York, New York


"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
D.S.
Miami Beach, Florida



  
Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.